A look at what's coming to Contemporary OBGYN this week.
A randomized trial suggests use of intrapartum extended-release nifedipine could help prevent severe hypertension among pregnant individuals with preeclampsia.
Results of the trial, which randomized 110 individuals, suggest use of nifedipine was associated with reducing in intrapartum acute hypertensive therapy among individuals with preeclampsia with severe features, with further analysis pointing to a lower rate of cesarean delivery compared with placebo therapy.
The controversial 17α-hydroxyprogesterone caproate (17-OHPC; Makena) showed to be ineffective at preventing preterm birth, according to briefing documents.
The United States Food and Drug Administration (FDA) is calling for withdrawal of the approval for 17α-hydroxyprogesterone caproate (17-OHPC; Makena) after briefing documents were released ahead of a 3-day advisory committee meeting.
Tamara Tobias, ARNP, WHNP-BC recently led a lecture at during the Nurse Practitioners in Women’s Health (NPWH) 25th Annual Premier Women’s Health Conference, held in Houston, Texas from September 28 to October 2, 2022. The lecture included several case studies and highlighted key takeaways from each.
Check back soon for additional updates!
EHR-based models show promise in predicting postpartum depression
December 24th 2024Recent research published highlights the potential of electronic health record data to improve postpartum depression diagnosis, offering a step toward better mental health outcomes for birthing parents.
Read More
Midlife sexual health boosts for nonheterosexual women reported
December 23rd 2024A recent study highlights improved sexual function and reduced distress among nonheterosexual women during menopause compared to their heterosexual counterparts, shedding light on how sexual identity impacts well-being.
Read More